Johnson & Johnson — SEC Form 4 Filings
SEC Form 4 Data
Track insider buying and selling activity for Johnson & Johnson (JNJ). Data sourced from SEC EDGAR Form 4 filings and analyzed by StoxPulse AI for significance.
9
$20.1M total
11
$43.7M total
0.8x
Neutral Signal
20
Form 4 transactions
Buy − Sell value
Sale · Feb 17, 2026
REED · Buy
Johnson & Johnson insiders filed 20 Form 4 transactions in the period analyzed: 9 purchases totaling $20.1M and 11 sales totaling $43.7M. That puts the buy-to-sell ratio at 0.82, which we read as neutral on a directional basis.
The most active filer was REED JOHN C with 7 transactions in this window. 10 of the 20 filings are flagged as routine — typically 10b5-1 scheduled trades rather than discretionary signals.
Form 4 filings are point-in-time disclosures and do not constitute investment advice. Routine sales under pre-arranged 10b5-1 plans should not be read as bearish.
| Insider | Title | Type | Shares | Price | Value | Date |
|---|---|---|---|---|---|---|
| REED JOHN C | EVP, Innovative Medicine, R&D | Buy | 25,255 | $0.00 | $0.00 | 2026-05-01 |
| REED JOHN C | EVP, Innovative Medicine, R&D | Sale | 11,002 | $229.85 | $2.5M | 2026-05-01 |
| Decker Robert J | VP Corporate Controller | Buy | 4,075 | $115.67 | $471K | 2026-02-27 |
| Decker Robert J | VP Corporate Controller | Sale | 4,075 | $247.87 | $1.0M | 2026-02-27 |
| Schmid Timothy | EVP, WW Chair, MedTech | Sale | 1,322 | $245.66 | $325K | 2026-02-20 |
| Swanson James D. | EVP, CIO | Buy | 20,521 | $164.62 | $3.4M | 2026-02-17 |
| Swanson James D. | EVP, CIO | Sale | 20,521 | $242.70 | $5.0M | 2026-02-17 |
| Wolk Joseph J | Exec VP, CFO | Buy | 19,241 | $115.67 | $2.2M | 2026-02-17 |
| Wolk Joseph J | Exec VP, CFO | Sale | 19,241 | $242.99 | $4.7M | 2026-02-17 |
| Wolk Joseph J | Exec VP, CFO | Buy | 12,066 | $129.51 | $1.6M | 2026-02-17 |
| Wolk Joseph J | Exec VP, CFO | Sale | 12,066 | $242.87 | $2.9M | 2026-02-17 |
| Wolk Joseph J | Exec VP, CFO | Buy | 33,386 | $131.94 | $4.4M | 2026-02-17 |
| Wolk Joseph J | Exec VP, CFO | Sale | 33,386 | $242.75 | $8.1M | 2026-02-17 |
| Wolk Joseph J | Exec VP, CFO | Sale | 24,961 | $242.68 | $6.1M | 2026-02-17 |
| REED JOHN C | EVP, Innovative Medicine, R&D | Buy | 21,721 | $157.92 | $3.4M | 2026-02-17 |
| REED JOHN C | EVP, Innovative Medicine, R&D | Sale | 21,721 | $243.00 | $5.3M | 2026-02-17 |
| REED JOHN C | EVP, Innovative Medicine, R&D | Buy | 29,927 | $156.15 | $4.7M | 2026-02-17 |
| REED JOHN C | EVP, Innovative Medicine, R&D | Sale | 29,927 | $243.00 | $7.3M | 2026-02-17 |
| REED JOHN C | EVP, Innovative Medicine, R&D | Sale | 2,283 | $243.00 | $555K | 2026-02-17 |
| Swanson James D. | EVP, CIO | Buy | 492 | $0.00 | $0.00 | 2026-02-15 |
Insider trading data for Johnson & Johnson (JNJ) is sourced directly from SEC Form 4 filings on the EDGAR database. Corporate insiders — including directors, officers, and shareholders owning more than 10% of the company — are legally required to report their transactions within two business days.
Insider purchases are often considered a bullish signal because executives are using their own money to buy shares, suggesting they believe the stock is undervalued. Insider sales, on the other hand, are more nuanced — they can reflect routine diversification plans (known as 10b5-1 plans), tax obligations, or genuine concerns about the company's outlook.
StoxPulse's AI system analyzes each JNJ insider transaction to determine whether it appears routine or notable. We track the buy/sell ratio, total transaction values, and patterns over time to provide a clear picture of insider sentiment for Johnson & Johnson.
AI earnings, financials, news & more
Translate any filing into plain English
Disclaimer: Insider trading data for Johnson & Johnson (JNJ) is sourced from SEC Form 4 filings and is provided for informational purposes only. Insider transactions should not be the sole basis for investment decisions. Always consult a qualified financial advisor.
Join the waitlist to receive instant AI notifications when Johnson & Johnson insiders buy or sell shares.
Join the Waitlist